• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HER2 靶向治疗的进展:从单克隆抗体到双抑制剂——癌症治疗的新突破。

Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment.

机构信息

Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru 570015 India.

Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru 570015 India.

出版信息

Bioorg Chem. 2024 Oct;151:107695. doi: 10.1016/j.bioorg.2024.107695. Epub 2024 Aug 9.

DOI:10.1016/j.bioorg.2024.107695
PMID:39137598
Abstract

HER2 receptors, overexpressed in certain human cancers, have drawn significant attention in cancer research due to their correlation with poor survival rates. Researchers have developed monoclonal antibodies like Trastuzumab and Pertuzumab against HER2 receptors, which have proven highly beneficial in cancer therapy. Bispecific antibodies like Zanidatamab and antibody-drug conjugates like T-DM1 have been developed to overcome the resistance associated with monotherapy. Small molecules such as Lapatinib, Neratinib, and Pyrotinib were initially developed for treating breast cancer. However, ongoing research is investigating their potential use in other types of cancer, often in combination with other medications. EGFR/HER2 dual-targeted drugs have overcome drug resistance associated with HER2-targeted monotherapy. This comprehensive review covers the structural characteristics of HER2, the HER family signaling pathway mechanism, recent findings regarding HER2 receptor involvement in various cancers, and diverse HER2-targeted therapies. This information provides a comprehensive understanding of HER2-targeted strategies in the evolving field of cancer treatment.

摘要

HER2 受体在某些人类癌症中过度表达,由于与生存率降低相关,因此在癌症研究中受到了极大关注。研究人员开发了针对 HER2 受体的单克隆抗体,如曲妥珠单抗和帕妥珠单抗,它们在癌症治疗中已被证明非常有效。双特异性抗体,如zanidatamab,和抗体药物偶联物,如 T-DM1,已被开发用于克服与单药治疗相关的耐药性。小分子药物,如拉帕替尼、奈拉替尼和吡咯替尼,最初是为治疗乳腺癌而开发的。然而,正在进行的研究正在调查它们在其他类型癌症中的潜在用途,通常与其他药物联合使用。EGFR/HER2 双重靶向药物克服了与 HER2 靶向单药治疗相关的耐药性。本综述全面介绍了 HER2 的结构特征、HER 家族信号通路机制、最近关于 HER2 受体在各种癌症中的作用的发现,以及各种 HER2 靶向治疗方法。这些信息为了解癌症治疗领域不断发展的 HER2 靶向策略提供了全面的认识。

相似文献

1
Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment.HER2 靶向治疗的进展:从单克隆抗体到双抑制剂——癌症治疗的新突破。
Bioorg Chem. 2024 Oct;151:107695. doi: 10.1016/j.bioorg.2024.107695. Epub 2024 Aug 9.
2
Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.在体内对曲妥珠单抗/帕妥珠单抗或 T-DM1 产生获得性耐药,可以通过使用 TAS0728 抑制 HER2 激酶来克服。
Cancer Sci. 2020 Jun;111(6):2123-2131. doi: 10.1111/cas.14407. Epub 2020 Apr 30.
3
Targeting the HER2 receptor in metastatic breast cancer.针对转移性乳腺癌中的HER2受体
Hematol Oncol Stem Cell Ther. 2012;5(3):127-37. doi: 10.5144/1658-3876.2012.127.
4
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.人表皮生长因子受体 2 阳性乳腺癌:曲妥珠单抗耐药的机制和新型靶向治疗。
Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75. doi: 10.1586/era.10.226.
5
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.曲妥珠单抗治疗 HER2 阳性转移性乳腺癌之外的新兴方法。
Ann Oncol. 2013 Oct;24(10):2492-2500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4.
6
New protein kinase inhibitors in breast cancer: afatinib and neratinib.乳腺癌中的新型蛋白激酶抑制剂:阿法替尼和来那替尼。
Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30.
7
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.曲妥珠单抗和酪氨酸激酶抑制剂治疗转移性乳腺癌的疗效。
Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Epub 2012 Oct 16.
8
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.优化HER2阳性乳腺癌的治疗结果:分子原理
Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16.
9
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.一种对具有ERBB配体过表达的耐药HER2+乳腺癌具有高活性的ERBB1-3中和抗体混合物。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.
10
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.在 HER2 过表达的肿瘤细胞中双重阻断 HER2 并不能完全消除 HER3 的功能。
Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5.

引用本文的文献

1
Design, optimization, and ADMET evaluation of S11a-0000168202: A promising LIMK1 inhibitor for gastric cancer treatment.S11a - 0000168202的设计、优化及ADMET评估:一种有前景的用于胃癌治疗的LIMK1抑制剂
PLoS One. 2025 May 14;20(5):e0323699. doi: 10.1371/journal.pone.0323699. eCollection 2025.